170 related articles for article (PubMed ID: 17179767)
1. Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy.
Lo Re V; Kostman JR; Gross R; Reddy KR; Mounzer K; Zemel BS; Rennert H; Stieritz DD; Putt M; Frank I; Strom BL
J Acquir Immune Defic Syndr; 2007 Mar; 44(3):344-50. PubMed ID: 17179767
[TBL] [Abstract][Full Text] [Related]
2. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
Bani-Sadr F; Lapidus N; Melchior JC; Ravaux I; Bensalem M; Rosa I; Cacoub P; Pol S; Perronne C; Carrat F
J Viral Hepat; 2008 Apr; 15(4):255-60. PubMed ID: 18307589
[TBL] [Abstract][Full Text] [Related]
3. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
[TBL] [Abstract][Full Text] [Related]
4. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Bani-Sadr F; Carrat F; Pol S; Hor R; Rosenthal E; Goujard C; Morand P; Lunel-Fabiani F; Salmon-Ceron D; Piroth L; Pialoux G; Bentata M; Cacoub P; Perronne C;
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):47-52. PubMed ID: 16123681
[TBL] [Abstract][Full Text] [Related]
6. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
Bräu N
J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
[TBL] [Abstract][Full Text] [Related]
7. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
Righi E; Beltrame A; Bassetti M; Lindstrom V; Mazzarello G; Dentone C; Di Biagio A; Ratto S; Viscoli C
Infection; 2008 Aug; 36(4):358-61. PubMed ID: 18642111
[TBL] [Abstract][Full Text] [Related]
8. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.
Laguno M; Milinkovic A; de Lazzari E; Murillas J; Martínez E; Blanco JL; Loncá M; Biglia A; Leon A; García M; Larrousse M; García F; Miró JM; Gatell JM; Mallolas J
Antivir Ther; 2005; 10(3):423-9. PubMed ID: 15918333
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic issues in HIV/HCV-coinfected patients.
Sulkowski MS; Benhamou Y
J Viral Hepat; 2007 Jun; 14(6):371-86. PubMed ID: 17501757
[TBL] [Abstract][Full Text] [Related]
12. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
Lerias de Almeida PR; Alves de Mattos A; Valle Tovo C
Ann Hepatol; 2010; 9(2):150-5. PubMed ID: 20526007
[TBL] [Abstract][Full Text] [Related]
13. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients.
Reiberger T; Payer BA; Kosi L; Heil PM; Rieger A; Peck-Radosavljevic M;
J Infect Dis; 2011 Jun; 203(12):1802-6. PubMed ID: 21606538
[TBL] [Abstract][Full Text] [Related]
14. Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection.
Sarmento-Castro R; Horta A; Vasconcelos O; Coelho H; Mendez J; Tavares AP; Seabra J; Duarte M; Chaves L; Fortes O; Recalde C; Ventura A; Pires N; Pinho L; Dias N; Carneiro F
J Infect; 2007 Jun; 54(6):609-16. PubMed ID: 17194480
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
[TBL] [Abstract][Full Text] [Related]
16. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients.
Zeremski M; Markatou M; Brown QB; Dorante G; Cunningham-Rundles S; Talal AH
J Acquir Immune Defic Syndr; 2007 Jul; 45(3):262-8. PubMed ID: 17414926
[TBL] [Abstract][Full Text] [Related]
17. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
[TBL] [Abstract][Full Text] [Related]
19. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
[TBL] [Abstract][Full Text] [Related]
20. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
